PrescribeWellness launches Vaccine Complete software solution
IRVINE, Calif. — PrescribeWellness on Tuesday announced the introduction of their newest software solution for community pharmacies, Vaccine Complete. The solution is aimed at streamlining the activities that accompany offering year-round immunizations.
“The pharmacist’s role in providing vaccinations in their community continues to expand,” said PrescribeWellness director of clinical services Farah Madhat said. “Increasingly, the overall health of the patient is more important than just counting the correct number of pills for them. Providing the appropriate vaccinations is a key part of overall health. Plus, it allows pharmacists to add valuable services to the patient appointment and practice at the top of their profession.”
Vaccine Complete identifies patients eligible for vaccination and includes outreach to patient groups that are recommended to receive certain vaccines. It also automates protocols with prescribers and meets state reporting mandates. Pharmacists will have bi-directional access to their state’s immunization registry through the PrescribeWellness Patient Engagement Center, powered by a partnership with health informatics company Scientific Technologies Corp. The solution was developed using insights from thousands of community pharmacies and PrescribeWellness’ Pharmacy Advisory Board.
“It is a solution for pharmacists that has been built by pharmacists,” PrescribeWellness CEO Al Babbington said. “Our staff of pharmacy clinicians have worked collaboratively with retail community pharmacists to create a solution that solves the challenges that our pharmacists have faced when trying to offer vaccinations.”
FDA expands age indication for Pfizer’s Prevnar 13 vaccine
SILVER SPRING, Md. — The Food and Drug Administration has expanded the age indication for Pfizer’s pneumococcal vaccine Prevnar 13. In addition to its previous indications for children aged 6 weeks to 17 years and adults over 50 years of age, the vaccine is now approved for use in adults 18 to 49 years of age.
“This expanded age indication in adults 18 to 49 offers an important public health benefit as appropriate vaccination against S. pneumoniae is critical to reducing the risk of pneumococcal disease, including in those with immunocompromising conditions," Pfizer Vaccines chief medical and scientific affairs officer Dr. Luis Jodar, Chief Medical and Scientific Affairs Officer, Pfizer Vaccines.
The expanded indication fits closer with the 2012 Centers for Disease Control and Prevention’s Advisory Committee on Immunizations Practice recommendations for adults 19 years of age and older with immunocompromising conditions.
Loading Post Please Wait...